RESEARCH

Leptin decreases BC cell susceptibility to NK lysis via PGC1A pathway

Hichem Bouguerra^{1,2}, Gorrab Amal¹, Stephan Clavel², Hamouda Boussen³, Jean-François Louet² and Asma Gati¹

¹Université Tunis El-Manar, Faculté des Sciences de Tunis, Laboratoire de Génétique, Immunologie et pathologies Humaines, Tunis, Tunisie

²Université Côte d'Azur, INSERM, C3M, Team Cellular and Molecular Physiopathology of Obesity and Diabetes, Nice, France

³Département d'Oncologie Médicale, Hôpital Abderrahman Mami, Ariana, Tunisia

Correspondence should be addressed to A Gati: asma.gati@fst.utm.tn

Abstract

Large prospective studies established a link between obesity and breast cancer (BC) development. Yet, the mechanisms underlying this association are not fully understood. Among the diverse adipocytokine secreted by hypertrophic adipose tissue, leptin is emerging as a key candidate molecule linking obesity and cancer, since it promotes proliferation and invasiveness of tumors. However, the potential implication of leptin on tumor escape mechanisms remains unknown. This study aims to explore the effect of leptin on tumor resistance to NK lysis and the underlying mechanism. We found that leptin promotes both BC resistance to NK92-mediated lysis and β oxidation on MCF-7, by the up-regulation of a master regulator of mitochondrial biogenesis, the peroxisome proliferator activated receptor coactivator-1 α (PGC1A). Using adenoviral approaches, we show that acute elevation of PGC1A enhances the fatty acid oxidation pathway and decreases the susceptibility of BC cells to NK92-mediated lysis. Importantly, we identified the involvement of PGC1A and leptin in the regulation of hypoxia inducible factor-1 α (HIF1A) expression by tumor cells. We further demonstrate that basal BC cells MDA-MB-231 and BT-20 exhibit an increased *PGC1A* mRNA level and an enhanced oxidative phosphorylation activity; in comparison with luminal BC cells MCF7 and MDA-361, which are associated with more resistance NK92 lysis. Altogether, our results demonstrate for the first time how leptin could promote tumor resistance to immune attacks. Reagents blocking leptin or PGC1A activity might aid in developing new therapeutic strategies to limit tumor development in obese BC patients.

Key Words:

- ▶ leptin
- ▶ breast cancer
- ▶ PGC-1 α
- ▶ tumor immune escape
- ▶ β oxidation

Endocrine Connections
(2020) **9**, 578–586

Introduction

The prevalence of obesity in the world has reached epidemic proportions in recent years. Epidemiological studies have established a positive association between obesity and the risk of developing different types of cancer including breast cancer (BC) (1, 2, 3). Obese BC patients exhibit a higher risk for lymph node metastasis, aggressive tumor, and mortality when compared with non-obese BC patients. Yet, the cellular and molecular mechanisms underlying this association remain poorly understood.

As it is known, adipocytes hypertrophy leads to deregulated secretions of pro-inflammatory chemokines,

cytokines and adipokines. Among various adipocytokines, leptin, a 16-kDa circulating hormone, is emerging as a key candidate mediator linking obesity with BC. Accumulated evidence supports this hypothesis: (1.) Hyperleptinemia and intratumoral leptin mRNA levels have been linked to a poor prognosis in BC patients (4), (2.) the leptin receptor (ObR) is highly expressed in primary and metastatic mammary carcinoma in comparison with normal tissues (5), and (3.) tumors transplanted into obese leptin receptor-deficient mice (db/db) grow much faster than tumors transplanted into lean (WT) mice (6).

The main role of leptin is to regulate energy homeostasis through the regulation of cellular metabolism. This adipokine has important additional effects, as in fact it is able to trigger a series of downstream signaling pathways, including both canonical (JAK2/STATs, MAPK/ERK 1/2, PI-3K/AKT) and non-canonical signaling pathways (JNK, p38 MAPK, PKC and AMPK), which promote proliferation, migration, and angiogenesis in BC (7). Yet, few studies have investigated the involvement of leptin on tumor/immune cells conflict. The main objective of this study was to explore the impact of leptin on tumor cell susceptibility to NK lysis. A more comprehensive assessment of the influence of this adipokine on tumor escape mechanisms may shed new light on the association between obesity and the poor prognosis for BC patients.

Materials and methods

Cell line and transient transfection experiments

MCF7, MDA-MB 361, BT20 and MDA-MB231 breast cancer cell lines were grown in RPMI 1640 medium with glucose (1 mg/mL) supplemented with 10% FCS, 100 U/mL penicillin and 100 mg/mL streptomycin (Life Technologies). The NK92 cell line was cultured in RPMI 1640/GlutaMAX supplemented with 10% of FCS and 300 U/mL recombinant human IL-2. Recombinant adenoviruses expressing PGC-1 α were kindly provided by Dr Pere Puigserver, Dana Farber Cancer institute (Boston, MA, USA). For adenoviral transduction experiments, adenoviruses were used as described (8).

Western blot analysis

Cells were cultured in six-well plates in serum-free medium, then treated with leptin and incubated for 48 h. For extraction of total soluble proteins from the cultured cells, the Mammalian Cell - PE LB™ kit (Genotech, St. Louis, MO) containing EDTA, DTT and protease inhibitor was used. Cell lysates were sonicated and subsequently centrifuged at 16,000 *g* for 10 min at 4°C, and clear supernatants were collected. For the Western blot analysis, 10% SDS-PAGE was used and proteins were transferred to Polyvinylidene difluoride membranes (Immobilon – P, Millipore). Primary antibodies against HIF1A and β -actin (ACTB) were purchased from Cell Signaling Technology. TFAM antibody was kindly provided by Dr Gustafsson, Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Sweden. Suitable secondary

IgG conjugated with HRP was used as secondary antibody. Immunodetection was performed using enhanced chemiluminescence (ECL system, Amersham Biosciences Inc.) according to the manufacturer's instructions.

RNA isolation and Real-time RT-PCR

Total RNA was extracted using RNeasy Mini Kit according to the manufacturer's protocol. cDNA was synthesized by using iScript cDNA Synthesis kit. Total RNA (1.0 μ g) was used as template for cDNA synthesis. For quantitative comparisons, cDNA samples were analyzed by real-time PCR using the SYBR green mix. Data were analyzed using the comparative cycle threshold (CT) method. RPLP0 was used as the internal loading control.

Flow cytometry analysis

The following monoclonal antibodies were used for flow cytometry: anti-TRAILR1-PE, anti-TRAILR2-PE, anti-Fas-PE and anti MHC-I-FITC, isotypic controls mouse IgG1 antibody from BD Pharmingen (San Diego, CA, USA) and anti-MICA/B-PE from R&D System. Samples were analyzed using an Acurri C6 flow cytometer (BD Biosciences, Le Pont de Claix, France). Data for at least 1×10^5 cells/sample were acquired and analyzed using Accuri C6 software.

Chromium release assay

Cytotoxicity was measured by a 4-h ^{51}Cr release. Different effector/target (E:T) ratios were used in the final volume of 200 μ L in 96-well plates. Experiments were performed in triplicate. After 4 h of co-culture, 40 μ L of the supernatants were transferred to LumaPlate-96 wells (PerkinElmer) and, after overnight drying, counted on a Packard Instrument TopCount NXT. Data were expressed as the percentage of specific ^{51}Cr release from target cells, calculated as: (experimental release – spontaneous release)/(maximum release – spontaneous release) $\times$ 100.

Relative mtDNA content measurements

Mitochondria DNA (mtDNA) was measured by quantitative PCR analysis of total DNA extracted from MCF7 cells by assessing the relative levels of cytochrome C oxidase 2 and the nuclear *App* gene (9).

Statistical analyses

One-way ANOVA and Student *t*-tests were used from Prism 5 software. $P < 0.05$ was designated as a statistically

significant difference. Statistical significance is represented in figures as follows: * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. All experiments were performed in triplicate and repeated at least three times, and all samples were analyzed in duplicate. The data were expressed as means $\pm$ s.d..

Results

Impairment of MCF-7 susceptibility to NK92 lysis by leptin

In order to explore the role of leptin in tumor immune escape, we investigated whether leptin alters NK92-mediated lysis of MCF-7 cells. As shown in Fig. 1A, leptin decreased significantly the susceptibility of MCF-7 to lysis by NK92 in a dose-dependent manner. Therefore, the molecular mechanism involved in the resistance of leptin treated MCF-7 to NK lysis was investigated. To this end, the expression of receptors involved in apoptosis Fas,

TRAILs (TRAILR1 and TRAILR2) and ligands of NK activatory and inhibitory receptors (MHC-I and MICA/B) were analyzed after leptin treatment. In comparison to non-treated cells, we found that leptin significantly down-regulates TRAILR1 and TRAILR2 expression (mean fluorescence intensity and percentage of positive cells) on MCF-7 cells. However, no effect was found on Fas, MICA/B or MHC-I expression (Fig. 1B).

Leptin stimulates fatty acid oxidation pathway in MCF-7 BC cells

Recent studies have indicated that the apoptotic network is incorporated into multiple cell physiological processes, including cell metabolism. Therefore, we investigated the effect of leptin on the metabolic proprieties of MCF-7 cells by checking the expression of several genes involved in glycolysis, lipogenesis and mitochondrial biogenesis. Our results revealed that, compared with basal conditions

Figure 1

Leptin decreases the susceptibility of MCF-7 to NK92 lysis. (A) The impact of leptin on MCF-7 tumor cells to NK92-mediated lysis was studied. MCF-7 were incubated with two concentrations of leptin for 48 h. Cytotoxicity was determined by a conventional 4-h Cr release assay at 20:1 and 2:1 ratios. Data shown represent the means $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$. (B) Analysis of surface expression of MHC-I, Fas, MICA/B, TRAILR1 and TRAILR2 was conducted on MCF-7 tumor cells treated for 48 h by two doses of leptin (10 ng: black line and 200 ng: red line). Isotypic control mAb was included; blue line.

(10 ng/mL), leptin at 100 ng/mL up-regulates the transcription of three important genes involved in mitochondrial oxidation function, carnitine palmitoyltransferase 1 (*CPT1*), cyclo oxygenase-2 (*COX2*) and ATP synthase (Fig. 2A). However, no significant effects on the lipogenic genes expression such as fatty acid synthase (*FASN*), sterol regulatory element binding protein (*SREBP*) and acetyl COA carboxylase (*ACC1*) were found (Fig. 2B). The impact of leptin on expression of

the glycolytic genes, *GLUT1*, *GLUT4*, *PFK*, *HK1* and *ALD*, was also tested. As shown in Fig. 2C, leptin was found to increase significantly the expression of *GLUT1*, with no effect noted on the other tested genes.

Leptin up-regulate PGC1A gene expression

To further dissect the molecular effect of leptin on the mitochondrial oxidative and respiratory functions, we thought to examine the gene expression status of several coregulators known to impact mitochondrial biogenesis and that are considered as 'master genes' susceptible to represent the missing link between fatty acid oxidation and resistance to NK92 lysis. The potential perturbations by leptin of gene expression levels of coactivators and corepressors such as the peroxisome proliferator-activated receptor- γ (*PPARG*) coactivator 1 α and 1 β (*PGC1A*, *PGC1B*), estrogen receptor- α (*ESR1*), estrogen-related receptor alpha and gamma (*ESRRA*, *ESRRG*) were studied. In Fig. 3, we showed that leptin increased the gene expression of *PGC1A* but had no impact on the gene expression of *PGC1B*, *ESR1*, *ESRRA* and *ESRRG*. These results indicate that leptin may enhance mitochondrial oxidative phosphorylation through the up-regulation of *PGC1A*.

PGC1A induces both oxidative phosphorylation and resistance of MCF7 to NK92-mediated lysis

The potential involvement of *PGC1A* on tumor resistance to NK92 lysis was then explored using adenoviral approaches. First, we evaluated the impact of *PGC1A* overexpression on mitochondrial oxidation. As shown in Fig. 4A, the overexpression of *PGC1A* markedly affected the gene expression of *COX2*, *CPT1*, and *TFAM* (transcription factor A of mitochondria) involved in the

Figure 2

Leptin stimulates fatty acid oxidation in MCF-7 cells. Analysis of leptin effect on expression of genes involved (A) in fatty acid oxidation, (B) in lipogenesis and (C) in glycolysis. MCF-7 cells were treated with 10 and 200 ng/mL of leptin for 48 h. Relative expression of mRNA was examined by real-time RT-PCR in leptin treated MCF-7 cells. RPLP0 was used as the internal loading control. Data shown represent the means $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

Figure 3

Leptin up-regulates *PGC1A* gene expression. Analysis of leptin impact on expression of genes involved in mitochondrial biogenesis. MCF-7 cells were treated with 10 and 200 ng/mL of leptin for 48 h. Relative expression of mRNA of coactivators and nuclear receptors was examined by real-time RT-PCR in leptin treated MCF-7 cells. RPLP0 was used as the internal loading control. Data shown represent the means $\pm$ s.d. * $P < 0.05$.

Figure 4

PGC1A promotes oxidative phosphorylation and resistance to NK92-mediated lysis. (A) *PGC1A* mRNA levels were overexpressed by adenovirus infection (48 h) of MCF-7 cells. The relative expression level of genes involved in oxidative phosphorylation pathway was evaluated by real-time RT-PCR. (B) Quantification of mitochondrial DNA (mtDNA) was evaluated by real-time RT-PCR. (C) Cytotoxicity was determined by a conventional 4-h Cr release assay at 20:1 and 2:1 ratios. Data shown represent the means $\pm$ s.d. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

expression of mitochondrial genome. While, no impact on the gene expression of *COX1*, *INOS* and *ACC1* was noticed. Besides, the relative abundance of mtDNA was consistently augmented in the PGC1A transfected cells in comparison with the control condition (Fig. 4B), suggesting therefore that overexpression of PGC1A enhances fatty acid oxidation in MCF-7 cells. Next, we evaluated the

susceptibility of control or PGC1A transfected MCF-7 cells after co-culturing them with NK92 lysis. As shown in Fig. 4C, MCF-7 BC cells overexpressing PGC1A were found to be more resistant to NK92-mediated lysis. These results underline for the first time the implication of the coactivator PGC1A, a powerful transcriptional regulator of mitochondria and oxidative metabolic programs, in BC tumor resistance to NK-mediated apoptosis.

PGC1A and leptin control HIF1A expression in MCF-7 BC cells

Given the key roles of hypoxia in tumor progression and survival, we asked whether PGC1A can affect HIF1A expression. We found that overexpression of PGC1A using adenovirus increased significantly HIF1A protein levels in MCF-7 cell lines (Fig. 5A). Real-time PCR analysis revealed, however, a slight induction of *HIF1A* mRNA levels upon elevation of PGC1A, further suggesting, therefore, that PGC1A mainly affects HIF-1 α protein accumulation rather than exerting a direct action on transcription of HIF1A gene message (Fig. 5B). In line with our results showing a positive association between leptin and PGC1A expression, we then analyzed the effect of leptin on HIF1A expression and found that leptin was able to increase HIF1A protein levels in a dose-dependent manner (Fig. 5C), without affecting its mRNA levels (Fig. 5D).

Basal BC cells exhibit enhanced PGC1A expression levels and are more resistant to NK92 lysis

To provide further evidence for the role of PGC1A in tumor development, we explore the possible relationship between PGC1A with tumor aggressiveness of BC cells.

Figure 5

PGC1A and leptin control HIF1A expression. (A) *PGC1A* mRNA levels were overexpressed by adenovirus infection (48 h) of MCF-7 cells. Whole-cell lysates were subjected to SDS-PAGE, blotted, and probed with anti-HIF1A, as indicated. β -actin (ACTB) was used as the loading control. (B) Relative expression of HIF1A mRNA was examined by real-time RT-PCR in PGC1A-infected MCF-7 cells. RPLP0 was used as the internal loading control. (C) After 48 h of incubation of MCF7 with different concentrations of leptin, whole-cell lysates were subjected to SDS-PAGE, blotted, and probed with anti-HIF1A. β -actin (ACTB) was used as the loading control. (D) Relative expression of HIF1A mRNA was examined by real-time RT-PCR in MCF-7 cells (48 h) treated with different concentrations of leptin. RPLP0 was used as the internal loading control. Data shown represent the means $\pm$ s.d. ** $P < 0.01$.

PGC1A gene expression was assessed in two basal cell lines with a high grade of invasiveness, BT20 and MDA-MB231, in comparison with two luminal BC cells with modest tumorigenic capacity *in vivo*, MDA-MB361 and MCF-7. Interestingly, our results revealed *PGC1A* mRNA levels as increased in the two basal cells compared to the luminal BC cells (Fig. 6A). Consistently, the direct *PGC1A* target gene, TFAM, was induced in the basal cells BT20 and MDA-MB231 (Fig. 6B), clearly confirming the functionality of *PGC1A*. Finally, to draw a link between high levels of *PGC1A*, increased oxidative phosphorylation status

and a resistance to NK-mediated lysis, the four BC cells were tested for susceptibility to NK92 lysis. Our results revealed a clear association between increased *PGC1A* gene expression and resistance to NK92 killing (Fig. 6C).

Altogether, these results establish a relationship between leptin, *PGC1A* gene activity, mitochondrial oxidative phosphorylation and tumor resistance to NK lysis (Fig. 7).

Discussion

The excessive accumulation of adipose tissue in obesity has been linked to poorer prognosis in BC (10). The stromal cells in a breast tumor microenvironment are mainly composed of adipocytes, and these cells can supply cancer

Figure 6

TNBC/basal BC cells exhibit enhanced *PGC1A* expression levels and are more resistant to NK lysis. (A) Relative expression of *PGC1A* mRNA was examined by real-time RT-PCR in two TNBC BC, BT20 and MDA-MB231, in comparison with two luminal BC cells, MDA-MB361 and MCF-7. RPLP0 was used as the internal loading control. (B) Whole-cell lysates were subjected to SDS-PAGE, blotted, and probed with anti-TFAM. β -actin (ACTB) was used as the loading control. (C) Susceptibility to NK92-mediated lysis of luminal and TNBC BC tumor cells was determined by a conventional 4-h Cr release assay at 20:1 and 2:1 ratios. Data shown represent the means $\pm$ s.d.

Figure 7

Working model depicting how leptin may promote MCF-7 resistance to apoptosis induced by NK cells while enhancing fatty acid oxidation through up-regulation of *PGC1A*.

cells with energy and can secrete many obesity-associated mediators, such as leptin, that can play a role in tumor development. Leptin can act in an endocrine, paracrine and autocrine manner, to promote BC proliferation and survival (11, 12). Several carcinogenic actions have been attributed to leptin, including the modulation of cell cycle regulator proteins and secretion of angiogenic proteins and migration (13, 14, 15). However, few studies focused on the effects of leptin in the conflict of tumor with immune cells.

This work showed that leptin, by enhancing fatty acid oxidation pathway, could promote tumor resistance to NK lysis. Multiple reports have suggested the involvement of this pathway in the promotion of survival and growth of malignant cells (16, 20). A recent report from Le bleu *et al.* has shown that tumor cells are able to up-regulate oxidative phosphorylation by enhancing mitochondrial respiration in order to generate the ATP required for primary tumor escape, relocation and metastases (21). The relevance of the involvement of the fatty acid oxidation on cell survival was further supported by the use of inhibitors of this pathway. Treatment with etomoxir or ranolazine inhibits the proliferation and sensitizes human leukemia cells to apoptosis (22). Similarly, the inhibition of lipid synthesis and oxidation through the inhibition of lipogenic enzymes, such as *FASN*, acetyl-coenzyme A (*ACACA*), *ACC* or *CPT1*, results in decreased proliferation and increased apoptosis of cancer cells (23, 24).

The activation of PGC1A by leptin could represent an important molecular strategy for cancer cells to escape immune cells. The overexpression of this transcriptional coregulatory using adenovirus promoted the accumulation of HIF1A, a key protein that is involved in angiogenesis and resistance of tumor cells to apoptosis. Increasing evidence indicates that HIF1A may modify the balance between pro- and anti-apoptotic factors, promoting, therefore, tumor resistance to immune cells. In this context, a study from Noman *et al.* showed that the induction of HIF1A is associated with alteration of non-small-cell lung carcinoma target susceptibility to CTL-mediated killing (25). An association of overexpression of HIF1A with poor treatment response and outcome has also been demonstrated in several human tumors (26, 27, 28). Although some studies reported the involvement of HIF1A in the regulation of anti-apoptotic proteins expression such as BCL2, inhibitor of apoptosis proteins IAP2 and survivin (29, 30), one should consider that the precise mechanism by which HIF1A inhibits apoptosis is still far from being fully understood, and it may be dependent of various cellular contexts. In addition to its impact on

anti-apoptotic proteins expression, HIF1A seems to be a major factor regulating leptin mRNA and protein expression. A report from Cascio *et al.* demonstrated that HIF1A binds multiple HRE motifs in the leptin promoter and induces expression of leptin in MCF-7 cells (31). Therefore, the overexpression of HIF1A by PGC1A may conduct to the maintenance of high leptin levels on obese patients. Nonetheless, we should mention that using adenovirus approach in our study we strongly increase *PGC1A* (150-fold higher), whereas leptin treatment increased *PGC1A* mRNA level by two fold.

Additionally, our data showed that basal BC cells, lacking ER, PR, and HER2 (32), express higher level of PGC1A and are more resistant to NK mediated lysis in comparison to the luminal BC cells. The role of PGC1A on the regulation of mitochondrial function and metabolism is well established; however, its impact on cancer metabolism and proliferation is only emerging. In BC, PGC1A has been previously shown to promote growth of tumors, regulate mitochondrial metabolism and endow angiogenic properties (33, 34). A recent study from Cai *et al.* reports that HIF1A and PGC1A may be promising biomarkers to identify subgroups of patients with poorer BC prognosis and to predict early and subclinical metastasis (35).

Overall, the present data demonstrate a key role of leptin in promoting tumor escape from anti-tumor immunity by enhancing fatty acid oxidation and tumor resistance to immune cells lysis. The potential use of leptin and PGC1A as plausible targets in the treatment of neoplastic progression of BC tumors deserves consideration, as it may constitute a promising therapeutic option for obese BC cancer patients.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was financially supported by the 'PHC Utique' program of the French Ministry of Foreign Affairs and Ministry of Higher Education and Research and the Tunisian Ministry of Higher Education and Scientific Research in the CMCU project number 13G0819.

Author contribution statement

A G designed research and revised the manuscript. H B performed research experiments and drafted the manuscript. A G and S A assisted with the research experiments and revised the manuscript. S C, H B, J F L helped to design research and revised the manuscript. All authors approved the final manuscript.

Acknowledgements

The authors thank Dr Pere Puigserver, Dana Farber Cancer institute (Boston, MA, USA), for providing PGC-1 α adenovirus and Dr Gustafsson, Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Sweden, for providing TFAM antibody.

References

- Barone I, Giordano C, Bonofiglio D, Ando S & Catalano S. Leptin, obesity and breast cancer: progress to understanding the molecular connections. *Current Opinion in Pharmacology* 2016 **31** 83–89. (<https://doi.org/10.1016/j.coph.2016.10.003>)
- Renehan AG, Tyson M, Egger M, Heller RF & Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet* 2008 **371** 569–578. ([https://doi.org/10.1016/S0140-6736\(08\)60269-X](https://doi.org/10.1016/S0140-6736(08)60269-X))
- Dawood S, Broglio K, Gonzalez-Angulo AM, Kau SW, Islam R, Hortobagyi GN & Cristofanilli M. Prognostic value of body mass index in locally advanced breast cancer. *Clinical Cancer Research* 2008 **14** 1718–1725. (<https://doi.org/10.1158/1078-0432.CCR-07-1479>)
- Miyoshi Y, Funahashi T, Tanaka S, Taguchi T, Tamaki Y, Shimomura I & Noguchi S. High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels. *International Journal of Cancer* 2006 **118** 1414–1419. (<https://doi.org/10.1002/ijc.21543>)
- Garofalo C, Koda M, Cascio S, Sulkowska M, Kanczuga-Koda L, Golaszewska J, Russo A, Sulkowski S & Surmacz E. Increased expression of leptin and the leptin receptor as a marker of breast cancer progression: possible role of obesity-related stimuli. *Clinical Cancer Research* 2006 **12** 1447–1453. (<https://doi.org/10.1158/1078-0432.CCR-05-1913>)
- Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, Berger NA & Reizes O. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. *Endocrine-Related Cancer* 2011 **18** 491–503. (<https://doi.org/10.1530/ERC-11-0102>)
- Guo S, Liu M, Wang G, Torroella-Kouri M & Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. *Biochimica et Biophysica Acta* 2012 **1825** 207–222. (<https://doi.org/10.1016/j.bbcan.2012.01.002>)
- Louet JF, Chopra AR, Sagen JV, An J, York B, Tannour-Louet M, Saha PK, Stevens RD, Wenner BR, Ilkayeva OR, *et al.* The coactivator SRC-1 is an essential coordinator of hepatic glucose production. *Cell Metabolism* 2010 **12** 606–618. (<https://doi.org/10.1016/j.cmet.2010.11.009>)
- Tyynismaa H, Sembongi H, Bokori-Brown M, Granycome C, Ashley N, Poulton J, Jalanko A, Spelbrink JN, Holt IJ & Suomalainen A. Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number. *Human Molecular Genetics* 2004 **13** 3219–3227. (<https://doi.org/10.1093/hmg/ddh342>)
- Bouguerra H, Guissouma H, Labidi S, Stambouli N, Marrakchi R, Chouaib S, Ben Ammar Elgaied A, Boussen H & Gati A. Breast cancer in Tunisia: association of body mass index with histopathological aspects of tumors. *Asian Pacific Journal of Cancer Prevention* 2014 **15** 6805–6810. (<https://doi.org/10.7314/apjcp.2014.15.16.6805>)
- Sanchez-Jimenez F, Perez-Perez A, de la Cruz-Merino L & Sanchez-Margalet V. Obesity and breast cancer: role of leptin. *Frontiers in Oncology* 2019 **9** 596. (<https://doi.org/10.3389/fonc.2019.00596>)
- Ando S, Gelsomino L, Panza S, Giordano C, Bonofiglio D, Barone I & Catalano S. Obesity, leptin and breast cancer: epidemiological evidence and proposed mechanisms. *Cancers* 2019 **11** 62. (<https://doi.org/10.3390/cancers11010062>)
- Gati A, Kouidhi S, Marrakchi R, El Gaaied A, Kourda N, Derouiche A, Chebil M, Caignard A & Perier A. Obesity and renal cancer: role of adipokines in the tumor-immune system conflict. *Oncoimmunology* 2014 **3** e27810. (<https://doi.org/10.4161/onci.27810>)
- Fan Y, Gan Y, Shen Y, Cai X, Song Y, Zhao F, Yao M, Gu J & Tu H. Leptin signaling enhances cell invasion and promotes the metastasis of human pancreatic cancer via increasing MMP-13 production. *Oncotarget* 2015 **6** 16120–16134. (<https://doi.org/10.18632/oncotarget.3878>)
- Saxena NK, Vertino PM, Anania FA & Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to cyclin D1 promoter via activation of Stat3. *Journal of Biological Chemistry* 2007 **282** 13316–13325. (<https://doi.org/10.1074/jbc.M609798200>)
- Blanquer-Rosselló MDM, Oliver J, Sastre-Serra J, Valle A & Roca P. Leptin regulates energy metabolism in MCF-7 breast cancer cells. *International Journal of Biochemistry and Cell Biology* 2016 **72** 18–26. (<https://doi.org/10.1016/j.biocel.2016.01.002>)
- Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB & Sabatini DM. Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. *Nature* 2014 **508** 108–112. (<https://doi.org/10.1038/nature13110>)
- Beloribi-Djeflaflia S, Vasseur S & Guillaumond F. Lipid metabolic reprogramming in cancer cells. *Oncogenesis* 2016 **5** e189. (<https://doi.org/10.1038/oncsis.2015.49>)
- Ackerman D & Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. *Trends in Cell Biology* 2014 **24** 472–478. (<https://doi.org/10.1016/j.tcb.2014.06.001>)
- Baenke F, Peck B, Miess H & Schulze A. Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. *Disease Models and Mechanisms* 2013 **6** 1353–1363. (<https://doi.org/10.1242/dmm.011338>)
- LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, *et al.* PGC-1 α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. *Nature Cell Biology* 2014 **16** 992–1003, 1001–1015. (<https://doi.org/10.1038/ncb3039>)
- Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeier H, *et al.* Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. *Journal of Clinical Investigation* 2010 **120** 142–156. (<https://doi.org/10.1172/JCI38942>)
- Brusselmans K, Vrolix R, Verhoeven G & Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. *Journal of Biological Chemistry* 2005 **280** 5636–5645. (<https://doi.org/10.1074/jbc.M408172000>)
- Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. *Nutrition* 2000 **16** 202–208. ([https://doi.org/10.1016/S0899-9007\(99\)00266-X](https://doi.org/10.1016/S0899-9007(99)00266-X))
- Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, *et al.* Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. *Cancer Research* 2011 **71** 5976–5986. (<https://doi.org/10.1158/0008-5472.CAN-11-1094>)
- Wilson WR & Hay MP. Targeting hypoxia in cancer therapy. *Nature Reviews: Cancer* 2011 **11** 393–410. (<https://doi.org/10.1038/nrc3064>)
- Ai Z, Lu Y, Qiu S & Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. *Cancer Letters* 2016 **373** 36–44. (<https://doi.org/10.1016/j.canlet.2016.01.009>)
- Moschetta MG, Maschio LB, Jardim-Perassi BV, Gelaleti GB, Lopes JR, Leonel C, Goncalves Ndo N, Ferreira LC, Martins GR, Borin TF, *et al.* Prognostic value of vascular endothelial growth factor and hypoxia-inducible factor 1 α in canine malignant mammary tumors.

- Oncology Reports* 2015 **33** 2345–2353. (<https://doi.org/10.3892/or.2015.3856>)
- 29 Chen YQ, Zhao CL & Li W. Effect of hypoxia-inducible factor-1alpha on transcription of survivin in non-small cell lung cancer. *Journal of Experimental and Clinical Cancer Research* 2009 **28** 29. (<https://doi.org/10.1186/1756-9966-28-29>)
- 30 Kilic M, Kasperczyk H, Fulda S & Debatin KM. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance. *Oncogene* 2007 **26** 2027–2038. (<https://doi.org/10.1038/sj.onc.1210008>)
- 31 Cascio S, Bartella V, Auriemma A, Johannes GJ, Russo A, Giordano A & Surmacz E. Mechanism of leptin expression in breast cancer cells: role of hypoxia-inducible factor-1alpha. *Oncogene* 2008 **27** 540–547. (<https://doi.org/10.1038/sj.onc.1210660>)
- 32 Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, *et al.* Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. *Modern Pathology* 2011 **24** 157–167. (<https://doi.org/10.1038/modpathol.2010.200>)
- 33 Deblois G, St-Pierre J & Giguere V. The PGC-1/ERR signaling axis in cancer. *Oncogene* 2013 **32** 3483–3490. (<https://doi.org/10.1038/onc.2012.529>)
- 34 Klimcakova E, Chenard V, McGuirk S, Germain D, Avizonis D, Muller WJ & St-Pierre J. PGC-1alpha promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply. *Cancer Research* 2012 **72** 1538–1546. (<https://doi.org/10.1158/0008-5472.CAN-11-2967>)
- 35 Cai FF, Xu C, Pan X, Cai L, Lin XY, Chen S & Biskup E. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. *Oncotarget* 2016 **7** 77793–77806. (<https://doi.org/10.18632/oncotarget.12796>)

Received in final form 7 May 2020

Accepted 21 May 2020

Accepted Manuscript published online 22 May 2020